Tags : Lexent

PharmaShots Weekly Snapshot (Jun 15-19, 2020)

 1.  Ultragenyx and Kyowa Kirin’s Crysvita (burosumab) Receive the US FDA’s Approval for the Treatment of Tumor-Induced Osteomalacia  Published: Jun 19, 2020 | Tags: Ultragenyx, Kyowa Kirin, Crysvita, burosumab, Receives, US, FDA, Approval, Treatment, Tumor-Induced Osteomalacia 2.  Pfizer and Sangamo’s Giroctocogene Fitelparvovec (SB-525) Demonstrate Positive Effect in P-I/II Alta Study for Hemophilia A Published: Jun 18, 2020 […]Read More

Foundation Medicine Acquires Lexent to Expand its Liquid Biopsy Platforms

Shots: Foundation Medicine acquires Lexent to accelerate the Foundation’s R&D strategy and expand its existing liquid biopsy platforms to advance cancer care for patients. The acquisition will boost Foundation Medicine’s capabilities to support adaptive clinical trial designs and accelerate therapeutic development in both early/ late-stage disease The addition of Lexent’s technology to Foundation’s portfolio of […]Read More